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ABSTRACT
Objective: The risk of fungal infection is one of the many concerns of patients admitted for chronic illness. The increase in fungal infection causes 
excessive morbidity and mortality. Despite the use of antifungals, the outcome of patients remains challenging. The study was performed to identify 
factors affecting the outcome of antifungal use.
Methods: A retrospective study was carried out in a local tertiary hospital for the past 1 year. Patients prescribed antifungals were included.
Results: A total of 145 patients who had been prescribed with antifungal agents within the past year were included in the study. It was noted that 
patients infected with fungi were mostly elderly patients (n=83, 57.2%). A majority of the patients (n=67, 46.2%, p<0.001) were diagnosed with or 
suspected to have systemic fungal infection compared to urinary fungal infection (n=31, 21.4%), oral fungal infection (n=20, 13.8%), pulmonary 
fungal infection (n=19, 13.1%), and others (n=8, 5.5%). As such, intravenous antifungal was the most commonly prescribed dosage form (n=88, 
60.7%, p<0.001). The mortality rate of patients with fungal infection was 35.9% (n=52). No significant factors were observed to affect the clinical 
outcome of patients. However, factors affecting survival outcome in patients treated for fungal infection were targeted treatment (p=0.036), less 
number of medications (p<0.001), and a higher number of antifungals prescribed (p=0.010).
Conclusion: A more comprehensive review of medication is required to ensure appropriate treatment is given to patients with fungal infection.
Keywords: Antifungal, Fungal infection, Outcome.
INTRODUCTION
The recent increase in the use of antineoplastic and immunosuppressive 
agents, prosthetic devices, grafts, and more aggressive surgery has 
contributed to the increase in invasive fungal infections [1,2]. Fungal 
infection causes excessive morbidity and mortality in patients at risk 
including patients undergoing blood and marrow transplantation, solid-
organ transplantation, major surgery, acquired immune deficiency 
syndrome, neoplastic disease, advanced age, and premature infants [3]. 
Apart from posing an important medical risk, fungal infection also 
causes an increase in financial burden due to longer use of hospital 
resources [4]. In view of this, the use of antifungal treatment should be 
done with care to ensure the optimum patient outcome.
Despite the use of antifungal agents, the outcome of fungal infection 
remains suboptimal and challenging [2]. The outcomes associated with 
invasive fungal infection are related to the severity of underlying host 
factors as well as the optimization of treatment-related factors [5]. 
Treatment-related factors include the speed of the initiation of 
antifungal therapy and the achievement of pharmacodynamic 
parameters [4]. As such, antifungal therapy should be initiated quickly 
to improve outcomes. However, early initiation of antifungal therapy 
is difficult to achieve due to relatively slow and insensitive diagnostic 
techniques. In addition, failures to achieve pharmacodynamic targets 
with the use of antifungals have also been associated with negative 
outcomes, and thus, dosing and appropriate serum levels also play an 
important role [5]. In view of the various factors that affect antifungal 
treatment, the effectiveness of antifungal agents is consistently being 
reviewed in the clinical setting in an attempt to optimize management 
and reduce resistance in the long run.
The high use of antifungals may expose the patient to the risk of 
resistance. Recent work has demonstrated that there is an increase 
in Candida resistance to first-line and second-line treatment [3,6]. 
Unfortunately, the available therapeutic options are limited. This 
poses a further problem as resistance increases additional days of 
admission [4]. The burden of resistance is especially a concern in 
immunocompromised patients. Therefore, identifying factors that 
optimize fungal management is vital.
Advances in medical technology, the widespread use of indwelling 
intravenous catheters, and the increased use of potent, broad-spectrum 
antimicrobial agents, have contributed to the dramatic increase in the 
incidence of fungal infections worldwide. Unfortunately, response rate 
remains suboptimal despite recent advances in antifungal therapy [4]. 
Although inadequate antimicrobial therapy has been shown to increase 
the risk for death in bacterial infections in many studies, few data 
investigating the effect of antifungal therapy on outcome of serious 
fungal disease are available [7], especially in the local setting. In view of 
this, it is vital to ensure that the use of antifungals is monitored closely 
to ensure that optimum treatment is given and problems such as the 
risk of resistance are minimized in the long run. This could provide 
vital information on measures that can be taken to improve antifungal 
use. Therefore, the aim of this study is to identify factors that affect the 
antifungal outcome in the local tertiary hospital.
METHODS
Study design
The study was conducted retrospectively in a local tertiary hospital. 
Data were collected from patients who had been prescribed with 
systemic antifungal agents within the past 1 year from pharmacy 
database and medical records. A list of antifungals available was 
identified from the local formulary. There were 11 antifungal agents 
in the formulary, which include: Nystatin, ketoconazole, itraconazole, 
caspofungin, amphotericin B, fluconazole, anidulafungin, flucytosine, 
posaconazole, voriconazole, and terbinafine. Only adult patients who 
had received at least one antifungal agent during this period were 
included in the study. Patients with incomplete data were excluded 
from the study. A list of patients who were prescribed these antifungals 
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was then generated using the pharmacy database. The following data 
were collected for each patient: Demographic data (name, registration 
number, age, gender, race, height, and weight), current medical 
problems, past medication history, social history, antifungal therapy, 
other drug therapy, laboratory investigation, culture and sensitivity 
test results, date of admission, date of discharge, and discharge status. 
Ethical approval was obtained from the local ethics committee (NF-
026-14).
Study definition
Some definitions used for this study include elderly which is defined 
as adults aged 60-year-old and above [8]. During the study, outcomes 
were defined based on two areas: Clinical or survival outcome. Clinical 
outcome was evaluated using a few parameters which were constantly 
monitored during admission: Efficacy (temperature, white blood 
count) and safety (liver function test and renal profile) [9,10]. Survival 
was defined as survival or death on discharge. Treatment strategies 
were defined as targeted antifungal treatment after a clear diagnosis 
of fungal infection, empirical treatment in symptomatic patients with 
suspected fungal infection, and prophylaxis treatment in patients at 
risk without any symptoms of infection.
Data analyzes
The collected data were analyzed using Statistical Package for Social 
Sciences (SPSS) version 22.0. Summary statistics of mean, range, 
and standard deviation (SD) were presented for numerical variables. 
Frequency and percentage were presented for categorical variables. 
Continuous data were analyzed using student’s T-test and ANOVA. For 
categorical response parameters, group comparisons were made using 
chi-square test. Logistic regression analysis was performed to examine 
the significance of individual variables in predicting the outcome of 




A total of 145 patients were included in the study. The majority of 
the patients (n=83, 57.2%) were elderly, with an overall mean age of 
59±16.6 years old. The different ethnics observed were Malay (n=82, 
56.6%), followed by Chinese (n=45, 31%), Indian (n=11, 7.6%), and 
others (n=7, 4.8%). Slightly more female patients (n=75, 51.7%) 
than males (n=70, 48.3%) were included in the study. A range of 1-4 
(mean±SD: 1.27±0.568) antifungals was prescribed to the patients 
during their admission. In average, patients had a long duration of 
admission (mean±SD: 28.9±21.365 days, range 3-123 days) and 
received an average of 15.12±5.992 (range 4-35) medications during 
their admission. Patients presented a mean of 4.83±2.142 (range 1-9) 
comorbidities apart from fungal infection. Less than half (n=52, 35.9%) 
of the patients died on discharge.
The prevalence and pattern of antifungal use
Fluconazole (111 cases), nystatin (30 cases), itraconazole (15 cases), 
and amphotericin B (13 cases) were the four most commonly 
prescribed antifungal agents in the study population. Among the study 
population, over half of the patients (n=85, 58.6%, p=0.046) showed 
positive fungal culture and sensitivity results. A majority of the patients 
(n=67, 46.2%, p<0.001) were diagnosed with or suspected to have 
systemic fungal infection, followed by urinary fungal infection (n=31, 
21.4%), oral fungal infection (n=20, 13.8%), pulmonary fungal infection 
(n=19, 13.1%), and others (n=8, 5.5%). A higher number of patients 
(n=88, 60.7%, p<0.001) received intravenous antifungal regimen as 
compared to oral route (n=37, 25.5%), intraperitoneal (n=1, 0.7%), 
and combination of oral and intravenous (n=19, 13.1%). There were 
three types of treatment strategies for fungal infection; prophylaxis, 
empirical, and targeted treatment. A significantly higher number 
of patients (n=95, 65.5%, p<0.001) were given targeted antifungal 
treatment after a clear diagnosis of fungal infection. Symptomatic 
patients with suspected fungal infection (n=37, 25.5%) were given 
empirical treatment. Patients at risk without any symptoms of infection 
(n=13, 9.0%) were given prophylaxis.
Outcome evaluation of antifungal use
Clinical outcome was evaluated based on efficacy and safety. 
Temperature and white blood count were used to evaluate the efficacy 
of antifungal use, whereas safety of antifungal use was evaluated based 
on liver and kidney function. In the study population, an average of 
2.72±2.79 days was taken for their body temperature to be normalized. 
An average of 3.74±3.68 days was taken for white blood cell to return 
normal. On the other hand, an average of 2.63±5.24 and 1.96±2.02 days 
were taken for a patient taking antifungals to develop an abnormality in 
liver and kidney function, respectively. Patients with a higher number of 
antifungals administered needed more time to develop an abnormality 
in liver function (r=0.249, p=0.047). However, no significant association 
was observed between treatment outcome of antifungal use and other 
variables such as age, race, gender, presence of positive culture and 
sensitivity, treatment strategy, the total number of medications, and 
number of co-morbidities.
When analyzing survival outcome, a total of 93 (64.1%) patients 
survived and was discharged during the study duration. Analyzes 
demonstrated that there were statistically significant associations 
between types of treatment and mortality (p=0.036), between number 
of medications and mortality (p<0.001), as well as between number 
of antifungals prescribed with mortality (p=0.010). Patients receiving 
targeted treatment was associated with a lower rate of mortality 
compared to empirical and prophylaxis (χ=6.66, p=0.036). A number of 
medications taken were higher (mean±SD: 18.52±6.16) in patients that 
died upon discharge as compared to patients who survived (mean±SD: 
13.23±5.00, p<0.001). Besides, patients who survived received more 
antifungals (mean±SD: 1.35±0.64) than patients who died on discharge 
(mean±SD: 1.12±0.38, p=0.010).
Factors affecting clinical and survival outcome
Clinical outcome was not influenced by the study factors. No statistically 
significant association between study variables with clinical outcome 
was observed. However, survival outcome was affected by three factors 
which included types of treatment, the number of medications and 
number of antifungals prescribed. Simple logistic regression was 
used to demonstrate how these factors affected survival outcome 
(Table 1). Empirical treatment was 2.179 times more likely to result in 
mortality than targeted treatment (p=0.049). Increasing the number 
of medications used was associated with an increased likelihood of 
death (odds ratio [OR]=1.191, p<0.001), and increasing the number 
of antifungal use was associated with a decreased likelihood of death 
(OR=0.368, p=0.022).
Further analysis using multiple logistic regression was performed 
to illustrate the effect of all these factors on survival (Table 2). After 
controlling effects of other factors, empirical treatment was 5.906 times 
more likely to cause death than targeted treatment (p=0.024). One 
unit increase in the number of medications used was associated with 
1.26 times (or 26%) more likely to result in death (p<0.001). Increasing 
the number of antifungals was less likely to cause death (OR=0.231, 
p=0.007).
DISCUSSION
One of the many concerns of patients admitted for chronic illness is 
the risk of fungal infection, similarly observed in the current work. 
Interestingly, nosocomial infection significantly increases the length of 
hospitalization [11]. This is due to the difficulty in eradicating fungi [6]. 
Evidently, a significant increase in the length of hospitalization has been 
previously demonstrated with an increase in co-morbidity index [12]. 
Although the current work demonstrates a higher proportion of Malay 
patients compared to other races, this reflects the racial population 
in Malaysia [8]. In the study population, it was noted that patients 
infected with fungi were mostly elderly patients. Age has been known 
to predispose patients to fungal infection with those above 50 years 
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being at a higher risk of fungal infection [13,14]. Fortunately, despite 
this, there were a significantly higher number of patients that survived 
as compared to patients that died during treatment for fungal infection, 
which demonstrates that with appropriate management, fungal 
infection can be treated.
In this study, the prevalence of systemic fungal infections was higher 
compared to localized fungal infection and as such intravenous 
antifungal agent was the most commonly prescribed dosage form in the 
study population. This is due to the requirement of a more intensive 
antifungal treatment and more rapid action for systemic fungal 
infection [15]. Despite approximately half of patients not showing 
positive fungal infection during culture and sensitivity tests, antifungal 
therapy was administered as a delay in administration of appropriate 
antifungal treatment is associated with worsened outcomes and higher 
mortality rates [15]. However, it was noted that despite a large amount 
of antifungal prescribed without positive culture, a significantly higher 
number of agents were given for targeted treatment as compared 
to prophylaxis and empirical management. Therefore, despite not 
obtaining positive cultures, the treatment was guided by other clinical 
symptoms which deemed the use of antifungal agents being classified 
as targeted treatment.
Clinical outcome of patients was assessed based on efficacy and 
safety of the agents given. The efficacy was based on the number of 
days the temperature and white cell count normalized, as previously 
described [9,10]. It was noted that normalization of these values was 
observed within 2-3 days in the present work. This demonstrates a 
good outcome of antifungal efficacy as guidelines recommend a change 
of antifungal after 2-3 days if patient conditions do not improve based 
on body temperature and level of white cell counts [10]. However, it 
should be noted that body temperature and white cell counts may not 
be the best indicator for evaluation of antifungal therapy efficacy, due to 
limitations such as the presence of other infections, use of antipyretics 
and presence of other co-morbidities [9]. Despite this, many studies use 
these parameters to compare the efficacy of treatment with appropriate 
success [9]. On the other hand, the safety of the agents was assessed 
based on effects on renal and liver. This is one of the major drawbacks 
in using antifungal agents, as toxicity may limit its use [16]. This present 
work, however, demonstrated an average of 1-2 days for abnormalities 
in liver or renal parameters to occur. Nonetheless, it should be noted 
that the abnormalities may not be directly related to antifungal use, as 
other factors such as a number of co-morbidities, diet, age, and other 
medication may affect renal and liver function [17,18].
Unfortunately, in view of the complexity of treating fungal infection 
and the severity of diseases patients present with, there was high 
mortality observed in the present work. However, mortality rates in 
patients treated with a fungal infection in other work have shown to 
be higher [19,20]. Interestingly, those that survived had a significantly 
higher number of antifungal agents given to them for targeted 
treatment compared to those that died. This indicated that a more 
aggressive approach in the management of fungal infection is required, 
as previously demonstrated [15]. However, patients that died also had 
a higher number of other medications than those that survived, which 
may indicate there was a higher risk of drug interaction or adverse 
reaction. Polypharmacy has been shown to have negative effects and 
thus, limiting the use of medications to those that are important may 
reduce drug-drug interaction and unwanted adverse effects [21].
In view of the complexity accompanying patients with fungal infection, 
various works have been performed to identify factors that predispose 
the patients to appropriate outcome. In this study population, it was 
observed that of the factors studied, three factors affected survival 
outcome. These were types of treatment, number of medications used 
and the number of antifungal prescribed. It was demonstrated that 
empirical treatment resulted in higher rate of mortality as compared 
to targeted treatment by more than five-fold. A delay in initiation of 
appropriate antifungal therapy has been associated with increased 
mortality [22]. However, if effective empiric antifungal therapy is 
administered, the mortality rate was shown to be reduced [23]. 
The need for appropriate targeted treatment is, therefore, vital. 
Furthermore, an increase in the number of antifungals was shown to 
decrease mortality rate in this present work. Introducing antifungal 
combination therapy is another possibility to improve the outcome 
and prognosis in immunocompromised or severely ill patients [24]. 
For example, combination antifungals have been shown to be more 
effective than monotherapy for invasive Aspergilosis [25]. The response 
rate and mortality of a cohort receiving antifungal combination therapy 
were also better than those receiving antifungal monotherapy [24]. 
Table 2: Multiple logistic regression of all factors that affect 
survival outcome
Variables B value OR 95% CI p value
Age
Elderly 0.076 1.097 0.392-2.973 0.883
Non-elderlya 1.000
Ethnic
Malay –1.008 0.365 0.051-2.635 0.318
Chinese –0.050 0.951 0.123-7.357 0.961




Female –0.571 0.565 0.231-1.381 0.211
Positive fungal C and S
Yes 1.147 3.150 0.674-14.718 0.145
Noa 1.000
Types of treatment
Prophylaxis 0.259 1.295 0.125-13.377 0.828
Empirical 1.776 5.906 1.269-27.487 0.024*
Targeted treatmenta 1.000
Number of medications 0.231 1.260 1.144-1.387 <0.001*
Number of comorbidities –0.072 0.931 0.724-1.196 0.575
Number of antifungals 
prescribed
–1.466 0.231 0.080-0.667 0.007*
CI stands for confidence interval, C and S stands for culture and sensitivity. 
aRepresents the reference category, *p<0.05 considered significant, OR: Odds 
ratio, CI: Confidence interval
Table 1: Simple logistic regression of factors affecting 
survival outcome
Variables B value OR 95% CI p value
Age
Elderly 0.276 1.318 0.660-2.632 0.435
Non-elderlya 1.000
Ethnic
Malay −0.536 0.585 0.122-2.808 0.503
Chinese 0.154 1.167 0.234-5.822 0.851




Female –0.592 0.553 0.279-1.100 0.091
Positive fungal C and S
Yes 0.442 1.556 0.771-3.140 0.218
Noa 1.000
Types of treatment
Prophylaxis –0.980 0.375 0.078-1.798 0.220
Empirical 0.779 2.179 1.005-4.727 0.049*
    Targeted treatmenta 1.000
Number of medications 0.174 1.191 1.105-1.283 <0.001*
Number of comorbidities 0.106 1.112 0.946-1.307 0.197
Number of antifungals 
prescribed
–0.998 0.368 0.157-0.864 0.022*
CI stands for confidence interval, C and S stands for culture and sensitivity. 
aRepresents the reference category, *p<0.05 considered significant, OR: Odds 
ratio, CI: Confidence interval
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However, despite this, it should be noted that an increase in the number 
of medications caused an increase in mortality. The risk of toxicity 
and drug-drug interaction increases with the number of medications 
given [26]. Thus, patients treated for fungal infection should have their 
medications reviewed thoroughly before adding to the list of treatment.
The aim of the study to identify factors that affect treatment and 
survival outcome in the local population were achieved. Factors that 
predicted survival in the local population were the use of more than 
one antifungal, less number of medications, and definitive treatment 
of fungal infection. Generalization of the study, however, should be 
done cautiously, due to the limitation in the retrospective nature and 
use of outcome parameters in this study. Therefore, further work 
in a prospective setting using a more specific parameter such as a 
combination of clinical, radiological, and mycological responses can be 
used in the future.
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